We were delighted to talk to Corey Siegel (Dartmouth-Hitchcock Medical Center, Lebanon, NH, US) around the IOIBD consensus statement on SARS-CoV-2 vaccination in patients with IBD.
Questions
- What issues were discussed at the consensus meeting of the International Organization for the Study of Inflammatory Bowel Disease (IOIBD) regarding the safety and effectiveness of SARS-CoV-2 vaccination in patients with IBD? (0:16)
- What methodology was used to produce the consensus statement? (1:07)
- What were the key recommendations of the IOIBD regarding SARS-CoV-2 vaccination for patients with IBD? (2:17)
- What statement was made around vaccination of pregnant women with IBD? (4:14)
- What are the remaining concerns and how will these be addressed? (5:18)
Disclosures: Consultant/Advisory Board for Abbvie, BMS, Celgene, Lilly, Janssen, Pfizer, Prometheus and Takeda; Speaker for CME activities for Abbvie, Celgene, Janssen, Pfizer and Takeda; Grant support from Crohn’s and Colitis Foundation, Leona M. and Harry B. Helmsley Charitable Trust, Abbvie, Janssen, Pfizer and Takeda.
Support: Interview and filming supported by Touch Medical Media.
